Business, News Clearside Biomedical, Inc. Completes Enrollment in Phase 2 Clinical Trial of CLS-TA Using Suprachoroidal Space (SCS™) Drug Administration by Business Wire • 2015/10/12 • 0 Comments ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, which develops drug therapies for eye diseases, announces completion of Phase 2 clinical trial enrollment for treatment of macular edema associated with non-infectious uveitis. Full Story →